Enumeration of CD3ˉCD56⁺CD16⁺ and NKG2D⁺ Natural Killer Cells in Breast Cancer Patients

Authors

  • Neelam Majeed Shalamar School of Allied Health Sciences, Lahore, Pakistan
  • Marwah Minhas Lecturer, University of Health Sciences, Lahore, Pakistan.
  • Romeeza Tahir Assistant Professor, Lecturer, University of Health Sciences, Lahore, Pakistan.
  • Faheem Shahzad Lecturer, University of Health Sciences, Lahore, Pakistan.
  • Bushra Munir Senior Lecturer, Shalamar School of Allied Health Sciences, Lahore, Pakistan.
  • Muhammad Kashif Professor, Bukhtawar Amin Medical and Dental College, Multan, Pakistan.
  • Afia Shahid Senior Lab Manager, Lecturer, University of Health Sciences, Lahore, Pakistan.
  • Nadeem Afzal Professor, Akhtar Saeed Medical and Dental College, Lahore, Pakistan.

Keywords:

Breast cancer, NK cells, NKG2D, CD56brightCD16, CD56dimCD16+

Abstract

Introduction: Breast cancer is a malignant disease of breast tissue. The immune system consists of cells, molecules, and organs that play a vital role in eliminating pathogens, toxins, allergens, and tumor cells. Cytotoxic T cells (CD8+) and natural killer (NK) cells are the major effector cells responsible for killing tumor cells.

Objective: This study was designed to determine the percentage of NK cells, NK cell subsets (CD56brightCD16- and CD56dimCD16+), and the activating receptor NKG2D in the peripheral blood of breast cancer patients.

Study Design: Prospective case control

Place and duration: This study was conducted between August 2017 and March 2018 at INMOL Hospital, Lahore, Pakistan.

Methodology: This was a comparative study that included 80 subjects (40 healthy controls and 40 breast cancer patients). The study included patients diagnosed with ductal carcinoma in situ (DCIS, n=6), invasive ductal carcinoma (IDC, n=33), and invasive lobular carcinoma (ILC, n=1). According to the American Cancer Society criteria (2017), the majority of patients were classified as grade 2 (n=25), followed by grade 3 (n=12) and grade 1 (n=3). Additionally, forty healthy controls, aged 26 to 60 years, with no history of malignancy or chronic disorders, were included.

Results: The mean ± SD of NK cells were higher in breast cancer patients (9.5 ± 5.2) compared to healthy controls (8.5 ± 5.3); however, the difference was not statistically significant (p = 0.39). The expression of NKG2D was higher in the control group (67 ± 16.3) compared to patients (52 ± 28.1), and this difference was statistically significant (p = 0.005). Breast cancer patients had a higher mean ± SD for the CD56bright subset (1.8 ± 1.1) compared to healthy controls (1.1 ± 0.5), and this difference was statistically significant (p = 0.001). Similarly, breast cancer patients had a higher mean ± SD for the CD56dim subset (12.4 ± 8.2) compared to healthy controls (11.2 ± 5.7); however, this difference was not statistically significant (p = 0.445).

Conclusion: The current study suggested that breast cancer patients modulate the abundance of NK cell subsets and alter the expression of NKG2D on the surface of peripheral blood NK cells which may decrease NK cell cytotoxicity. 

References

1. Tariq R, Huma S, Butt MZ, Amin F. Risk factors and prevalence of breast cancer. Students Corner. 2013;63(8):1075-1078.

2. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31(17):2205-2218.

3. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.

4. Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood: Do they mirror the situation in all organs? Immunol Lett. 2007;108(1):45-51.

5. Andrews DM, Smyth MJ. A potential role for RAG-1 in NK cell development revealed by analysis of NK cells during ontogeny. Immunol Cell Biol. 2010;88(2):107.

6. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010;115(11):2167-2176.

7. Mamessier E, Sylvain A, Thibult ML, et al. Human breast cancer cells enhance self-tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121(9):3609-3622.

8. Vankayalapati R, Garg A, Porgador A, et al. Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol. 2005;175(7):4611-4617.

9. Pesce S, Carlomagno S, Moretta A, Sivori S, Marcenaro E. Uptake of CCR7 by KIR2DS4. J Immunol Res. 2015.

10. Zamai L, Ponti C, Mirandola P, et al. NK cells and cancer. J Immunol. 2007;178(7):4011-4016.

11. Li X, Guo F, Liu Y, et al. NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients. Oncol Lett. 2015;10(3):1533-1540.

12. Smyth MJ, Cretney E, Kelly JM, et al. Activation of NK cell cytotoxicity. Mol Immunol. 2005;42:501-510.

13. Villegas FR, Coca S, Villarrubia VG, et al. Prognostic significance of tumor-infiltrating natural killer cell subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002;35(1):23-28.

14. Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88(3):577-583.

15. Takanami I, Takeuchi K, Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2001;121(6):1058-1063.

16. Garcia-Iglesias T, del Toro-Arreola A, Albarran-Somoza B, et al. Low NKp30, NKp46, and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer. 2009;9(1):186.

17. Jin S, Deng Y, Hao JW, et al. NK cell phenotypic modulation in lung cancer environment. PLoS One. 2014;9(10):e109976.

18. Pietra G, Manzini C, Rivara S, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 2012;72(6):1407-1415.

19. Schleypen JS, von Geldern M, Weiß EH, et al. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer. 2003;106(6):905-912.

20. Costello RT, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002;99(10):3661-3667.

21. Nieto-Velázquez NG, Torres-Ramos YD, Muñoz-Sánchez JL, et al. Altered expression of natural cytotoxicity receptors and NKG2D on peripheral blood NK cell subsets in breast cancer patients. Transl Oncol. 2016;9(5):384-391.

22. Komen.org. Breast cancer risk factors. Available at: https://www.komen.org/breast-cancer/risk-factor/. Accessed April 2019.

23. Mozaffari F, Lindemalm C, Choudhury A, et al. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer. 2007;97(1):105-111.

24. Mamessier E, Pradel LC, Thibult ML, et al. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol. 2013;190(5):2424-2436

Published

2024-12-30

Issue

Vol. 2 No. 2 (2024)

Section

Articles

License

Copyright (c) 2025 Neelam Majeed, Marwah Minhas, Romeeza Tahir, Faheem Shahzad, Bushra Munir, Muhammad Kashif, Afia Shahid, Nadeem Afzal

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under a CC-BY 4.0 License.